{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:10:44Z","timestamp":1790125844324,"version":"4.0.1"},"reference-count":106,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2024,9,30]]},"DOI":"10.18632\/oncotarget.28646","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T12:29:19Z","timestamp":1727699359000},"page":"644-658","source":"Crossref","is-referenced-by-count":17,"title":["<i>UBA1<\/i> dysfunction in VEXAS and cancer"],"prefix":"10.18632","volume":"15","author":[{"given":"Maki","family":"Sakuma","sequence":"first","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"},{"name":"Medical Graduate Center, Technical University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencke","family":"Walter","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic Mutations inand Severe Adult-Onset Autoinflammatory Disease","volume":"38","author":"Groarke","year":"2020","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia","volume":"13","author":"Walter","year":"2020","journal-title":"Blood"},{"key":"3","doi-asserted-by":"publisher","first-page":"103386","DOI":"10.1016\/j.retram.2023.103386","article-title":"New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia","volume":"7","author":"Izzo","year":"2023","journal-title":"Curr Res Transl Med"},{"key":"4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41584-022-00778-4","article-title":"Disorders of ubiquitylation: unchained inflammation","volume":"1","author":"Aksentijevich","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"5","doi-asserted-by":"publisher","first-page":"e503","DOI":"10.1038\/bcj.2016.112","article-title":"The role of the proteasome in AML","volume":"6","author":"Sachs","year":"2016","journal-title":"Blood Cancer J"},{"key":"6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","article-title":"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"1","author":"Orlowski","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41375-018-0167-0","article-title":"Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia","volume":"3","author":"Hyer","year":"2019","journal-title":"Leukemia"},{"key":"9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nm.4474","article-title":"A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment","volume":"2","author":"Griffin","year":"2018","journal-title":"Nat Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1126\/science.1149200","article-title":"Cancer proliferation gene discovery through functional genomics","volume":"31","author":"Chang","year":"2008","journal-title":"Science"},{"key":"11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a Cancer Dependency Map","volume":"17","author":"Goodale","year":"2017","journal-title":"Cell"},{"key":"12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pharmrev.120.000053","article-title":"E1 Enzymes as Therapeutic Targets in Cancer","volume":"7","author":"Schimmer","year":"2021","journal-title":"Pharmacol Rev"},{"key":"13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jama.2022.24836","article-title":"Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population","volume":"32","author":"Schwartz","year":"2023","journal-title":"JAMA"},{"key":"14","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41375-023-01857-5","article-title":"Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies","volume":"3","author":"Walter","year":"2023","journal-title":"Leukemia"},{"key":"15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/art.42802","article-title":"VEXAS-Defining UBA1 Somatic Variants in 245,368 Diverse Individuals in the NIH All Of Us Cohort","volume":"7","author":"Bick","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023723","article-title":"Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes","author":"Gurnari","year":"2024","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10875-022-01258-w","article-title":"A High-Throughput Amplicon Screen for Somatic UBA1 Variants in Cytopenic and Giant Cell Arteritis Cohorts","volume":"4","author":"Savic","year":"2022","journal-title":"J Clin Immunol"},{"key":"18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrm2673","article-title":"Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways","volume":"1","author":"Harper","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"19","doi-asserted-by":"publisher","first-page":"e1000131","DOI":"10.1371\/journal.pgen.1000131","article-title":"E1 ubiquitin-activating enzyme UBA-1 plays multiple roles throughout C. elegans development","volume":"4","author":"Smith","year":"2008","journal-title":"PLoS Genet"},{"key":"20","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/ncb2804","article-title":"Uba1 functions in Atg7- and Atg3-independent autophagy","volume":"1","author":"Baehrecke","year":"2013","journal-title":"Nat Cell Biol"},{"key":"21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0014-4827(82)90004-0","article-title":"A temperature-sensitive mutant isolated from mouse FM3A cells defective in DNA replication at a non-permissive temperature","volume":"13","author":"Suzuki","year":"1982","journal-title":"Exp Cell Res"},{"key":"22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/BF01233196","article-title":"Isolation of temperature-sensitive CHO-K1 cell mutants exhibiting chromosomal instability and reduced DNA synthesis at nonpermissive temperature","volume":"1","author":"Hori","year":"1990","journal-title":"Somat Cell Mol Genet"},{"key":"23","first-page":"26","article-title":"Isolation of temperature-sensitive cell cycle mutants from mouse FM3A cells. Characterization of mutants with special reference to DNA replication","volume":"26","author":"Ui","year":"1990","journal-title":"J Biol Chem"},{"key":"24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1247\/csf.17.113","article-title":"Complementation by a cloned human ubiquitin-activating enzyme E1 of the S-phase-arrested mouse FM3A cell mutant with thermolabile E1","volume":"1","author":"Seno","year":"1992","journal-title":"Cell Struct Funct"},{"key":"25","first-page":"15726","article-title":"A Chinese hamster cell cycle mutant arrested at G2 phase has a temperature-sensitive ubiquitin-activating enzyme, E1","volume":"26","author":"Marcus","year":"1988","journal-title":"J Biol Chem"},{"key":"26","first-page":"2060","article-title":"Purification, characterization, and rapid inactivation of thermolabile ubiquitin-activating enzyme from the mammalian cell cycle mutant ts85","volume":"26","author":"Ciechanover","year":"1989","journal-title":"J Biol Chem"},{"key":"27","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/0006-291x(92)90692-e","article-title":"tsBN75 and tsBN423, temperature-sensitive x-linked mutants of the BHK21 cell line, can be complemented by the ubiquitin-activating enzyme E1 cDNA","volume":"18","author":"Nishimoto","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4161\/fly.4285","article-title":"Mutation of the gene encoding the ubiquitin activating enzyme ubal causes tissue overgrowth in Drosophila","volume":"1","author":"Hariharan","year":"2007","journal-title":"Fly (Austin)"},{"key":"29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1242\/dev.011288","article-title":"The E1 ubiquitin-activating enzyme Uba1 in Drosophila controls apoptosis autonomously and tissue growth non-autonomously","volume":"13","author":"Bergmann","year":"2008","journal-title":"Development"},{"key":"30","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.1038\/s41467-023-43262-7","article-title":"An adaptive stress response that confers cellular resilience to decreased ubiquitination","volume":"1","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"31","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s44318-024-00046-z","article-title":"Shared and distinct mechanisms of UBA1 inactivation across different diseases","volume":"4","author":"Likhite","year":"2024","journal-title":"EMBO J"},{"key":"32","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1101\/gad.350752.123","article-title":"Translational regulation by uORFs and start codon selection stringency","volume":"3","author":"Hinnebusch","year":"2023","journal-title":"Genes Dev"},{"key":"33","first-page":"33171","article-title":"Human ubiquitin-activating enzyme, E1. Indication of potential nuclear and cytoplasmic subpopulations using epitope-tagged cDNA constructs","volume":"26","author":"Schwartz","year":"1994","journal-title":"J Biol Chem"},{"key":"34","doi-asserted-by":"publisher","first-page":"10895","DOI":"10.1074\/jbc.272.16.10895","article-title":"Identification of a region within the ubiquitin-activating enzyme required for nuclear targeting and phosphorylation","volume":"27","author":"Schwartz","year":"1997","journal-title":"J Biol Chem"},{"key":"35","doi-asserted-by":"publisher","first-page":"16188","DOI":"10.1073\/pnas.0607769103","article-title":"Impaired nucleotide excision repair upon macrophage differentiation is corrected by E1 ubiquitin-activating enzyme","volume":"10","author":"Hanawalt","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"36","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1042\/bj3000701","article-title":"Nuclear localization of the ubiquitin-activating enzyme, E1, is cell-cycle-dependent","volume":"30","author":"Schwartz","year":"1994","journal-title":"Biochem J"},{"key":"37","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/blood.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"14","author":"Kermani","year":"2022","journal-title":"Blood"},{"key":"38","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood.2020010286","article-title":"Novel somatic mutations in UBA1 as a cause of VEXAS syndrome","volume":"13","author":"Beck","year":"2021","journal-title":"Blood"},{"key":"39","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in VEXAS syndrome: insights from a retrospective series","volume":"13","author":"Sujobert","year":"2021","journal-title":"Blood"},{"key":"40","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1093\/rheumatology\/keab524","article-title":"Atypical splice-site mutations causing VEXAS syndrome","volume":"6","author":"Kosmider","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"41","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/art.42471","article-title":"Novel Somatic UBA1 Variant in a Patient With VEXAS Syndrome","volume":"7","author":"Vencovsky","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"42","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/ajh.27320","article-title":"Distinct bone marrow findings associated with a noncanonical UBA1 variant in VEXAS syndrome","volume":"9","author":"Mason","year":"2024","journal-title":"Am J Hematol"},{"key":"43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41589-023-01497-x","article-title":"DeKinomics pulse-chases kinase functions in living cells","volume":"2","author":"Wang","year":"2024","journal-title":"Nat Chem Biol"},{"key":"44","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/bjh.19021","article-title":"S56F UBA1 variant is associated with haematological predominant subtype of VEXAS","volume":"20","author":"Savic","year":"2023","journal-title":"Br J Haematol"},{"key":"45","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1182\/blood.2022018774","article-title":"Spectrum of clonal hematopoiesis in VEXAS syndrome","volume":"14","author":"Xie","year":"2023","journal-title":"Blood"},{"key":"46","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients","volume":"18","author":"Aouba","year":"2022","journal-title":"Br J Dermatol"},{"key":"47","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","article-title":"Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1","volume":"5","author":"Cardona","year":"2021","journal-title":"Blood Adv"},{"key":"48","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41467-024-44811-4","article-title":"VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation","volume":"1","author":"Lazaro","year":"2024","journal-title":"Nat Commun"},{"key":"49","doi-asserted-by":"publisher","first-page":"7445","DOI":"10.1182\/bloodadvances.2023010531","article-title":"Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome","volume":"7","author":"Belizaire","year":"2023","journal-title":"Blood Adv"},{"key":"50","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225640","article-title":"Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX","author":"Comont","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"51","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41577-023-00838-0","article-title":"Control of immune cell function by the unfolded protein response","volume":"2","author":"Huang","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"52","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nri.2016.62","article-title":"The unfolded protein response in immunity and inflammation","volume":"1","author":"Blumberg","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrm3270","article-title":"The unfolded protein response: controlling cell fate decisions under ER stress and beyond","volume":"1","author":"Hetz","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"54","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.molcel.2017.06.017","article-title":"The Unfolded Protein Response and Cell Fate Control","volume":"6","author":"Papa","year":"2018","journal-title":"Mol Cell"},{"key":"55","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/ajcp\/aqad186","article-title":"Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: A single-institution longitudinal study of 111 bone marrow samples from 52 patients","volume":"16","author":"Gibson","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"56","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2352-3026(23)00375-7","article-title":"Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond","volume":"1","author":"Kosmider","year":"2024","journal-title":"Lancet Haematol"},{"key":"57","doi-asserted-by":"publisher","first-page":"101160","DOI":"10.1016\/j.xcrm.2023.101160","article-title":"Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS","volume":"4","author":"Ombrello","year":"2023","journal-title":"Cell Rep Med"},{"key":"58","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.19.594376","article-title":"Single-cell genotype-phenotype mapping identifies therapeutic vulnerabilities in VEXAS syndrome","author":"Marro","year":"2024","journal-title":"bioRxiv"},{"key":"59","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ajh.27156","article-title":"VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management","volume":"9","author":"Patnaik","year":"2024","journal-title":"Am J Hematol"},{"key":"60","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"13","author":"Goodnough","year":"2019","journal-title":"Blood"},{"key":"61","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1182\/blood.2021013472","article-title":"The role of iron in chronic inflammatory diseases: from mechanisms to treatment options in anemia of inflammation","volume":"14","author":"Muckenthaler","year":"2022","journal-title":"Blood"},{"key":"62","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1182\/blood.2022015724","article-title":"Erythroblastic islands foster granulopoiesis in parallel to terminal erythropoiesis","volume":"14","author":"Grimes","year":"2022","journal-title":"Blood"},{"key":"63","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"14","author":"Vial","year":"2022","journal-title":"Blood"},{"key":"64","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1093\/rheumatology\/keab349","article-title":"A Case of polychondritis-onset refractory organizing pneumonia with cytopaenia diagnosed as VEXAS syndrome: the disease course of 7 years","volume":"6","author":"Kaneko","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"65","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1182\/blood-2006-10-055350","article-title":"beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation","volume":"10","author":"Verdier","year":"2007","journal-title":"Blood"},{"key":"66","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1158\/0008-5472.CAN-15-1756","article-title":"Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41","volume":"7","author":"List","year":"2016","journal-title":"Cancer Res"},{"key":"67","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1182\/blood-2009-06-227033","article-title":"Ubiquitination and degradation of the thrombopoietin receptor c-Mpl","volume":"11","author":"Hitchcock","year":"2010","journal-title":"Blood"},{"key":"68","doi-asserted-by":"publisher","first-page":"8316","DOI":"10.1073\/pnas.0914496107","article-title":"c-Cbl deficiency leads to diminished lymphocyte development and functions in an age-dependent manner","volume":"10","author":"Flavell","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"69","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ni907","article-title":"Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1","volume":"4","author":"Glimcher","year":"2003","journal-title":"Nat Immunol"},{"key":"70","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1182\/blood-2012-05-356014","article-title":"The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans","volume":"12","author":"Lozano","year":"2012","journal-title":"Blood"},{"key":"71","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1128\/mcb.14.3.1997-2003.1994","article-title":"Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway","volume":"1","author":"Ozer","year":"1994","journal-title":"Mol Cell Biol"},{"key":"72","doi-asserted-by":"publisher","first-page":"rkae065","DOI":"10.1093\/rap\/rkae065","article-title":"Targeting enhanced cell death represents a potential therapeutic strategy for VEXAS syndrome","volume":"8","author":"Nakajima","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"73","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/ard-2023-224819","article-title":"Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry","volume":"8","author":"Lacombe","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"74","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.4049\/jimmunol.1203227","article-title":"Adaptive immunity does not strongly suppress spontaneous tumors in a Sleeping Beauty model of cancer","volume":"19","author":"Dupuy","year":"2013","journal-title":"J Immunol"},{"key":"75","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1093\/rheumatology\/kead472","article-title":"Three UBA1 clones for a unique VEXAS syndrome","volume":"6","author":"Terriou","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"76","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood.2023020772","article-title":"VEXAS: walking on the edge of malignancy","volume":"14","author":"Malcovati","year":"2023","journal-title":"Blood"},{"key":"77","doi-asserted-by":"publisher","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"36","author":"Ebert","year":"2019","journal-title":"Science"},{"key":"78","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Wong","year":"2022","journal-title":"Lancet Haematol"},{"key":"79","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.4161\/cc.19978","article-title":"Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage","volume":"1","author":"Bartek","year":"2012","journal-title":"Cell Cycle"},{"key":"80","doi-asserted-by":"publisher","first-page":"e201800096","DOI":"10.26508\/lsa.201800096","article-title":"Recruitment of ubiquitin-activating enzyme UBA1 to DNA by poly(ADP-ribose) promotes ATR signalling","volume":"1","author":"Constantinou","year":"2018","journal-title":"Life Sci Alliance"},{"key":"81","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41588-021-00920-0","article-title":"Genomic and evolutionary classification of lung cancer in never smokers","volume":"5","author":"Hofman","year":"2021","journal-title":"Nat Genet"},{"key":"82","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1038\/s41467-019-13266-3","article-title":"Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network","volume":"1","author":"Haupt","year":"2019","journal-title":"Nat Commun"},{"key":"83","doi-asserted-by":"publisher","first-page":"eaba3066","DOI":"10.1126\/science.aba3066","article-title":"The impact of sex on gene expression across human tissues","volume":"36","author":"Aguet","year":"2020","journal-title":"Science"},{"key":"84","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13293-021-00387-y","article-title":"Sexual dimorphism of monocyte transcriptome in individuals with chronic low-grade inflammation","volume":"1","author":"Lamon-Fava","year":"2021","journal-title":"Biol Sex Differ"},{"key":"85","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ajmg.c.31800","article-title":"Genes that escape from X-chromosome inactivation: Potential contributors to Klinefelter syndrome","volume":"18","author":"Brown","year":"2020","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"86","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ajhg.2007.09.009","article-title":"Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy","volume":"8","author":"Baumbach-Reardon","year":"2008","journal-title":"Am J Hum Genet"},{"key":"87","doi-asserted-by":"publisher","first-page":"e1606","DOI":"10.1002\/mgg3.1606","article-title":"A novel Xp11.22-22.33 deletion suggesting a possible mechanism of congenital cervical spinal muscular atrophy","volume":"9","author":"Yang","year":"2021","journal-title":"Mol Genet Genomic Med"},{"key":"88","doi-asserted-by":"publisher","first-page":"8411","DOI":"10.1523\/JNEUROSCI.0775-14.2014","article-title":"Ubiquitin-activating enzyme activity contributes to differential accumulation of mutant huntingtin in brain and peripheral tissues","volume":"3","author":"Li","year":"2014","journal-title":"J Neurosci"},{"key":"89","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.molmed.2015.08.003","article-title":"UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration","volume":"2","author":"Gillingwater","year":"2015","journal-title":"Trends Mol Med"},{"key":"90","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1172\/JCI71318","article-title":"Dysregulation of ubiquitin homeostasis and \u03b2-catenin signaling promote spinal muscular atrophy","volume":"12","author":"Lamont","year":"2014","journal-title":"J Clin Invest"},{"key":"91","doi-asserted-by":"publisher","first-page":"e87908","DOI":"10.1172\/jci.insight.87908","article-title":"Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy","volume":"1","author":"Parson","year":"2016","journal-title":"JCI Insight"},{"key":"92","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nature04256","article-title":"Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival","volume":"43","author":"Yang","year":"2005","journal-title":"Nature"},{"key":"93","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/rheumatology\/kev294","article-title":"Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study","volume":"5","author":"Launay","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"94","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.leukres.2016.02.005","article-title":"Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"4","author":"Berthier","year":"2016","journal-title":"Leuk Res"},{"key":"95","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1097\/HS9.0000000000000661","article-title":"Azacytidine Treatment for VEXAS Syndrome","volume":"5","author":"Valk","year":"2021","journal-title":"Hemasphere"},{"key":"96","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.leukres.2015.06.007","article-title":"Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia","volume":"3","author":"Longinotti","year":"2015","journal-title":"Leuk Res"},{"key":"97","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-022-00615-7","article-title":"Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients","volume":"1","author":"Binder","year":"2022","journal-title":"Blood Cancer J"},{"key":"98","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","article-title":"A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML","volume":"3","author":"Rauzy","year":"2022","journal-title":"Leukemia"},{"key":"99","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1002\/hem3.129","article-title":"Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome","volume":"8","author":"Raaijmakers","year":"2024","journal-title":"Hemasphere"},{"key":"100","doi-asserted-by":"publisher","first-page":"20265","DOI":"10.18632\/oncotarget.24750","article-title":"Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity","volume":"9","author":"Saville","year":"2018","journal-title":"Oncotarget"},{"key":"101","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41419-021-04023-w","article-title":"GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death","volume":"1","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"key":"102","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-21-0344","article-title":"Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer","volume":"2","author":"Schimmer","year":"2022","journal-title":"Clin Cancer Res"},{"key":"103","doi-asserted-by":"publisher","first-page":"9472","DOI":"10.1158\/0008-5472.CAN-07-0568","article-title":"Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics","volume":"6","author":"Beutler","year":"2007","journal-title":"Cancer Res"},{"key":"104","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1038\/s41467-023-40537-x","article-title":"Auranofin targets UBA1 and enhances UBA1 activity by facilitating ubiquitin trans-thioesterification to E2 ubiquitin-conjugating enzymes","volume":"1","author":"Huang","year":"2023","journal-title":"Nat Commun"},{"key":"105","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1158\/0008-5472.CAN-13-2033","article-title":"Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia","volume":"7","author":"Byrd","year":"2014","journal-title":"Cancer Res"},{"key":"106","doi-asserted-by":"publisher","first-page":"9118","DOI":"10.18632\/oncotarget.2361","article-title":"Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr\/Abl-dependent and -independent mechanisms","volume":"5","author":"Carter","year":"2014","journal-title":"Oncotarget"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T14:33:07Z","timestamp":1727706787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,9,30]]}},"alternative-id":["28646"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28646","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}